nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxorubicin—ABCC3—Rifampicin—leprosy	0.188	0.283	CbGbCtD
Doxorubicin—ABCB11—Rifampicin—leprosy	0.162	0.245	CbGbCtD
Doxorubicin—ABCC1—Rifampicin—leprosy	0.115	0.174	CbGbCtD
Doxorubicin—ABCC2—Rifampicin—leprosy	0.0852	0.129	CbGbCtD
Doxorubicin—CYP2B6—Rifampicin—leprosy	0.0542	0.0818	CbGbCtD
Doxorubicin—ABCB1—Rifampicin—leprosy	0.0278	0.0419	CbGbCtD
Doxorubicin—CYP3A4—Rifampicin—leprosy	0.0166	0.0251	CbGbCtD
Doxorubicin—CYP3A4—Dapsone—leprosy	0.0137	0.0207	CbGbCtD
Doxorubicin—NOS3—hindlimb—leprosy	0.00474	0.0514	CbGeAlD
Doxorubicin—NOS3—appendage—leprosy	0.00406	0.0441	CbGeAlD
Doxorubicin—NOS1—nerve—leprosy	0.00379	0.0411	CbGeAlD
Doxorubicin—NOS2—IL23-mediated signaling events—IL23R—leprosy	0.00316	0.0626	CbGpPWpGaD
Doxorubicin—NOS1—blood vessel—leprosy	0.00298	0.0323	CbGeAlD
Doxorubicin—NOS2—tendon—leprosy	0.00289	0.0314	CbGeAlD
Doxorubicin—AURKA—Menadione—Thalidomide—leprosy	0.00261	0.724	CbGdCrCtD
Doxorubicin—NDUFS7—Respiratory electron transport—SDHD—leprosy	0.00227	0.0449	CbGpPWpGaD
Doxorubicin—NDUFS3—Respiratory electron transport—SDHD—leprosy	0.00227	0.0449	CbGpPWpGaD
Doxorubicin—NOS3—blood vessel—leprosy	0.00226	0.0246	CbGeAlD
Doxorubicin—NOS1—Latent infection of Homo sapiens with Mycobacterium tuberculosis—SLC11A1—leprosy	0.00217	0.043	CbGpPWpGaD
Doxorubicin—NDUFS2—Respiratory electron transport—SDHD—leprosy	0.00213	0.0422	CbGpPWpGaD
Doxorubicin—AKR1A1—eye—leprosy	0.00209	0.0227	CbGeAlD
Doxorubicin—SLC22A16—testis—leprosy	0.00198	0.0215	CbGeAlD
Doxorubicin—NDUFS7—Electron Transport Chain—SDHD—leprosy	0.00196	0.0389	CbGpPWpGaD
Doxorubicin—NDUFS3—Electron Transport Chain—SDHD—leprosy	0.00196	0.0389	CbGpPWpGaD
Doxorubicin—NDUFS7—Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.—SDHD—leprosy	0.00192	0.038	CbGpPWpGaD
Doxorubicin—NDUFS3—Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.—SDHD—leprosy	0.00192	0.038	CbGpPWpGaD
Doxorubicin—NDUFS2—Electron Transport Chain—SDHD—leprosy	0.00184	0.0366	CbGpPWpGaD
Doxorubicin—AKR1A1—skin of body—leprosy	0.00182	0.0197	CbGeAlD
Doxorubicin—NDUFS2—Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.—SDHD—leprosy	0.0018	0.0357	CbGpPWpGaD
Doxorubicin—CBR3—tendon—leprosy	0.00179	0.0195	CbGeAlD
Doxorubicin—SLC22A16—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC11A1—leprosy	0.00166	0.033	CbGpPWpGaD
Doxorubicin—NOS2—Latent infection of Homo sapiens with Mycobacterium tuberculosis—SLC11A1—leprosy	0.00164	0.0324	CbGpPWpGaD
Doxorubicin—NOS1—eye—leprosy	0.00158	0.0172	CbGeAlD
Doxorubicin—NDUFS2—eye—leprosy	0.00157	0.0171	CbGeAlD
Doxorubicin—ABCB8—testis—leprosy	0.00154	0.0167	CbGeAlD
Doxorubicin—ABCB8—nervous system—leprosy	0.00151	0.0164	CbGeAlD
Doxorubicin—CBR3—testis—leprosy	0.00148	0.0161	CbGeAlD
Doxorubicin—NDUFS7—The citric acid (TCA) cycle and respiratory electron transport—SDHD—leprosy	0.00148	0.0293	CbGpPWpGaD
Doxorubicin—NDUFS3—The citric acid (TCA) cycle and respiratory electron transport—SDHD—leprosy	0.00148	0.0293	CbGpPWpGaD
Doxorubicin—CBR3—nervous system—leprosy	0.00146	0.0158	CbGeAlD
Doxorubicin—ABCC6—eye—leprosy	0.00144	0.0156	CbGeAlD
Doxorubicin—NDUFS2—The citric acid (TCA) cycle and respiratory electron transport—SDHD—leprosy	0.00139	0.0275	CbGpPWpGaD
Doxorubicin—AKR1A1—tendon—leprosy	0.00138	0.015	CbGeAlD
Doxorubicin—NDUFS2—skin of body—leprosy	0.00137	0.0149	CbGeAlD
Doxorubicin—YWHAG—eye—leprosy	0.00135	0.0147	CbGeAlD
Doxorubicin—NDUFS3—skin of body—leprosy	0.00135	0.0147	CbGeAlD
Doxorubicin—Lactic dehydrogenase activity increased—Thalidomide—leprosy	0.00129	0.00672	CcSEcCtD
Doxorubicin—Lymphopenia—Thalidomide—leprosy	0.00129	0.00672	CcSEcCtD
Doxorubicin—DHCR7—skin of body—leprosy	0.00128	0.014	CbGeAlD
Doxorubicin—NOS3—Latent infection of Homo sapiens with Mycobacterium tuberculosis—SLC11A1—leprosy	0.00127	0.0252	CbGpPWpGaD
Doxorubicin—NDUFS7—tendon—leprosy	0.00126	0.0137	CbGeAlD
Doxorubicin—Skin exfoliation—Dapsone—leprosy	0.00123	0.00642	CcSEcCtD
Doxorubicin—RALBP1—eye—leprosy	0.00122	0.0133	CbGeAlD
Doxorubicin—Venous thrombosis—Thalidomide—leprosy	0.00122	0.00638	CcSEcCtD
Doxorubicin—Vesiculobullous rash—Thalidomide—leprosy	0.00118	0.00614	CcSEcCtD
Doxorubicin—AURKA—tendon—leprosy	0.00117	0.0127	CbGeAlD
Doxorubicin—AKR1A1—testis—leprosy	0.00115	0.0124	CbGeAlD
Doxorubicin—CBR1—eye—leprosy	0.00114	0.0124	CbGeAlD
Doxorubicin—Blood lactate dehydrogenase increased—Thalidomide—leprosy	0.00113	0.00592	CcSEcCtD
Doxorubicin—Gastric ulcer—Thalidomide—leprosy	0.00113	0.00592	CcSEcCtD
Doxorubicin—AKR1A1—nervous system—leprosy	0.00112	0.0122	CbGeAlD
Doxorubicin—Enlargement abdomen—Thalidomide—leprosy	0.0011	0.00572	CcSEcCtD
Doxorubicin—Febrile neutropenia—Thalidomide—leprosy	0.0011	0.00572	CcSEcCtD
Doxorubicin—Serum creatinine increased—Thalidomide—leprosy	0.00107	0.00559	CcSEcCtD
Doxorubicin—NOS1—tendon—leprosy	0.00105	0.0114	CbGeAlD
Doxorubicin—Myasthenia—Thalidomide—leprosy	0.00105	0.00547	CcSEcCtD
Doxorubicin—Psoriasis—Thalidomide—leprosy	0.00105	0.00547	CcSEcCtD
Doxorubicin—NDUFS2—tendon—leprosy	0.00104	0.0113	CbGeAlD
Doxorubicin—NDUFS7—testis—leprosy	0.00104	0.0113	CbGeAlD
Doxorubicin—Hypomagnesaemia—Thalidomide—leprosy	0.00104	0.00542	CcSEcCtD
Doxorubicin—Oral candidiasis—Thalidomide—leprosy	0.00104	0.00542	CcSEcCtD
Doxorubicin—NDUFS3—tendon—leprosy	0.00103	0.0112	CbGeAlD
Doxorubicin—Embolism—Thalidomide—leprosy	0.00103	0.00536	CcSEcCtD
Doxorubicin—NDUFS7—nervous system—leprosy	0.00102	0.0111	CbGeAlD
Doxorubicin—Nail disorder—Thalidomide—leprosy	0.00102	0.00531	CcSEcCtD
Doxorubicin—TOP2A—Menadione—Thalidomide—leprosy	0.000998	0.276	CbGdCrCtD
Doxorubicin—CBR1—skin of body—leprosy	0.000994	0.0108	CbGeAlD
Doxorubicin—AURKA—testis—leprosy	0.000968	0.0105	CbGeAlD
Doxorubicin—Seborrhoeic dermatitis—Thalidomide—leprosy	0.000967	0.00505	CcSEcCtD
Doxorubicin—AURKA—nervous system—leprosy	0.00095	0.0103	CbGeAlD
Doxorubicin—Burning sensation—Thalidomide—leprosy	0.000948	0.00495	CcSEcCtD
Doxorubicin—Neuralgia—Thalidomide—leprosy	0.000948	0.00495	CcSEcCtD
Doxorubicin—Hypercalcaemia—Thalidomide—leprosy	0.000948	0.00495	CcSEcCtD
Doxorubicin—Hepatomegaly—Thalidomide—leprosy	0.000931	0.00486	CcSEcCtD
Doxorubicin—Thrombosis—Thalidomide—leprosy	0.000931	0.00486	CcSEcCtD
Doxorubicin—Lung disorder—Thalidomide—leprosy	0.000931	0.00486	CcSEcCtD
Doxorubicin—Nystagmus—Thalidomide—leprosy	0.000923	0.00482	CcSEcCtD
Doxorubicin—NQO1—eye—leprosy	0.000915	0.00994	CbGeAlD
Doxorubicin—Hyperlipidaemia—Thalidomide—leprosy	0.000914	0.00477	CcSEcCtD
Doxorubicin—YWHAG—tendon—leprosy	0.000897	0.00974	CbGeAlD
Doxorubicin—Neuritis—Thalidomide—leprosy	0.000883	0.00461	CcSEcCtD
Doxorubicin—Albuminuria—Thalidomide—leprosy	0.000883	0.00461	CcSEcCtD
Doxorubicin—NOS1—testis—leprosy	0.000868	0.00943	CbGeAlD
Doxorubicin—NDUFS2—testis—leprosy	0.000863	0.00937	CbGeAlD
Doxorubicin—Pleural effusion—Thalidomide—leprosy	0.00086	0.00449	CcSEcCtD
Doxorubicin—Amblyopia—Thalidomide—leprosy	0.000853	0.00446	CcSEcCtD
Doxorubicin—NDUFS3—testis—leprosy	0.000852	0.00926	CbGeAlD
Doxorubicin—NOS1—nervous system—leprosy	0.000852	0.00925	CbGeAlD
Doxorubicin—NDUFS2—nervous system—leprosy	0.000847	0.0092	CbGeAlD
Doxorubicin—Skin ulcer—Thalidomide—leprosy	0.000846	0.00442	CcSEcCtD
Doxorubicin—Hyperaesthesia—Thalidomide—leprosy	0.00084	0.00438	CcSEcCtD
Doxorubicin—NDUFS3—nervous system—leprosy	0.000836	0.00908	CbGeAlD
Doxorubicin—Nasopharyngitis—Dapsone—leprosy	0.000836	0.00436	CcSEcCtD
Doxorubicin—Rash pustular—Thalidomide—leprosy	0.000826	0.00431	CcSEcCtD
Doxorubicin—Muscular weakness—Dapsone—leprosy	0.000824	0.0043	CcSEcCtD
Doxorubicin—RALBP1—tendon—leprosy	0.00081	0.0088	CbGeAlD
Doxorubicin—DHCR7—testis—leprosy	0.00081	0.00879	CbGeAlD
Doxorubicin—Influenza—Dapsone—leprosy	0.000808	0.00422	CcSEcCtD
Doxorubicin—Petechiae—Thalidomide—leprosy	0.000801	0.00418	CcSEcCtD
Doxorubicin—NOS3—tendon—leprosy	0.000797	0.00866	CbGeAlD
Doxorubicin—NQO1—skin of body—leprosy	0.000796	0.00865	CbGeAlD
Doxorubicin—NQO1—Apoptosis-related network due to altered Notch3 in ovarian cancer—RIPK2—leprosy	0.000796	0.0158	CbGpPWpGaD
Doxorubicin—DHCR7—nervous system—leprosy	0.000795	0.00863	CbGeAlD
Doxorubicin—Pancreatitis—Dapsone—leprosy	0.000792	0.00413	CcSEcCtD
Doxorubicin—Blood disorder—Thalidomide—leprosy	0.000789	0.00412	CcSEcCtD
Doxorubicin—NOS2—IL12-mediated signaling events—RIPK2—leprosy	0.000757	0.015	CbGpPWpGaD
Doxorubicin—CBR1—tendon—leprosy	0.000756	0.00822	CbGeAlD
Doxorubicin—SLC22A16—SLC-mediated transmembrane transport—SLC11A1—leprosy	0.000756	0.015	CbGpPWpGaD
Doxorubicin—Amenorrhoea—Thalidomide—leprosy	0.00075	0.00392	CcSEcCtD
Doxorubicin—Vasodilation procedure—Thalidomide—leprosy	0.00075	0.00392	CcSEcCtD
Doxorubicin—Vasodilation—Thalidomide—leprosy	0.00075	0.00392	CcSEcCtD
Doxorubicin—Jaundice cholestatic—Thalidomide—leprosy	0.00075	0.00392	CcSEcCtD
Doxorubicin—AKR1C3—tendon—leprosy	0.000747	0.00811	CbGeAlD
Doxorubicin—YWHAG—testis—leprosy	0.000743	0.00807	CbGeAlD
Doxorubicin—Photosensitivity reaction—Dapsone—leprosy	0.000737	0.00385	CcSEcCtD
Doxorubicin—Viral infection—Thalidomide—leprosy	0.00073	0.00381	CcSEcCtD
Doxorubicin—Skin discolouration—Thalidomide—leprosy	0.00073	0.00381	CcSEcCtD
Doxorubicin—Bone disorder—Thalidomide—leprosy	0.00073	0.00381	CcSEcCtD
Doxorubicin—YWHAG—nervous system—leprosy	0.000729	0.00792	CbGeAlD
Doxorubicin—Arthropathy—Thalidomide—leprosy	0.000725	0.00378	CcSEcCtD
Doxorubicin—Hyperbilirubinaemia—Thalidomide—leprosy	0.000725	0.00378	CcSEcCtD
Doxorubicin—Cellulitis—Thalidomide—leprosy	0.000725	0.00378	CcSEcCtD
Doxorubicin—Hypocalcaemia—Thalidomide—leprosy	0.00072	0.00376	CcSEcCtD
Doxorubicin—Thinking abnormal—Thalidomide—leprosy	0.00072	0.00376	CcSEcCtD
Doxorubicin—Herpes simplex—Thalidomide—leprosy	0.000715	0.00373	CcSEcCtD
Doxorubicin—Oliguria—Thalidomide—leprosy	0.000715	0.00373	CcSEcCtD
Doxorubicin—Hyperuricaemia—Thalidomide—leprosy	0.00071	0.00371	CcSEcCtD
Doxorubicin—ABCB11—testis—leprosy	0.000708	0.00769	CbGeAlD
Doxorubicin—Neuropathy peripheral—Dapsone—leprosy	0.000706	0.00369	CcSEcCtD
Doxorubicin—Dyskinesia—Thalidomide—leprosy	0.000701	0.00366	CcSEcCtD
Doxorubicin—Creatinine increased—Thalidomide—leprosy	0.000692	0.00362	CcSEcCtD
Doxorubicin—Bone pain—Thalidomide—leprosy	0.000688	0.00359	CcSEcCtD
Doxorubicin—POR—tendon—leprosy	0.000682	0.00741	CbGeAlD
Doxorubicin—Atrioventricular block—Thalidomide—leprosy	0.000679	0.00355	CcSEcCtD
Doxorubicin—Sinusitis—Dapsone—leprosy	0.000676	0.00353	CcSEcCtD
Doxorubicin—Gait disturbance—Thalidomide—leprosy	0.000675	0.00353	CcSEcCtD
Doxorubicin—Blood uric acid increased—Thalidomide—leprosy	0.000671	0.0035	CcSEcCtD
Doxorubicin—Coordination abnormal—Thalidomide—leprosy	0.000671	0.0035	CcSEcCtD
Doxorubicin—RALBP1—testis—leprosy	0.000671	0.00729	CbGeAlD
Doxorubicin—Neck pain—Thalidomide—leprosy	0.000667	0.00348	CcSEcCtD
Doxorubicin—NOS3—testis—leprosy	0.00066	0.00717	CbGeAlD
Doxorubicin—Hepatocellular injury—Thalidomide—leprosy	0.000659	0.00344	CcSEcCtD
Doxorubicin—Pulmonary embolism—Thalidomide—leprosy	0.000659	0.00344	CcSEcCtD
Doxorubicin—Phosphatase alkaline increased—Thalidomide—leprosy	0.000659	0.00344	CcSEcCtD
Doxorubicin—RALBP1—nervous system—leprosy	0.000658	0.00715	CbGeAlD
Doxorubicin—NOS3—nervous system—leprosy	0.000648	0.00704	CbGeAlD
Doxorubicin—Hyperkalaemia—Thalidomide—leprosy	0.000647	0.00338	CcSEcCtD
Doxorubicin—Eructation—Thalidomide—leprosy	0.000647	0.00338	CcSEcCtD
Doxorubicin—CYP1B1—eye—leprosy	0.000643	0.00698	CbGeAlD
Doxorubicin—Pharyngitis—Dapsone—leprosy	0.000642	0.00335	CcSEcCtD
Doxorubicin—TOP2A—tendon—leprosy	0.000636	0.00691	CbGeAlD
Doxorubicin—Colitis—Thalidomide—leprosy	0.000633	0.0033	CcSEcCtD
Doxorubicin—Candida infection—Thalidomide—leprosy	0.000629	0.00329	CcSEcCtD
Doxorubicin—Skin exfoliation—Thalidomide—leprosy	0.000629	0.00329	CcSEcCtD
Doxorubicin—CBR1—testis—leprosy	0.000626	0.0068	CbGeAlD
Doxorubicin—Blood urea increased—Thalidomide—leprosy	0.000622	0.00325	CcSEcCtD
Doxorubicin—ABCB8—Transmembrane transport of small molecules—SLC11A1—leprosy	0.000622	0.0123	CbGpPWpGaD
Doxorubicin—Neuropathy—Thalidomide—leprosy	0.000619	0.00323	CcSEcCtD
Doxorubicin—Aplastic anaemia—Thalidomide—leprosy	0.000619	0.00323	CcSEcCtD
Doxorubicin—AKR1C3—testis—leprosy	0.000619	0.00672	CbGeAlD
Doxorubicin—CBR1—nervous system—leprosy	0.000615	0.00668	CbGeAlD
Doxorubicin—Dry eye—Thalidomide—leprosy	0.000609	0.00318	CcSEcCtD
Doxorubicin—NQO1—tendon—leprosy	0.000606	0.00658	CbGeAlD
Doxorubicin—Cramps of lower extremities—Thalidomide—leprosy	0.000605	0.00316	CcSEcCtD
Doxorubicin—Tinnitus—Dapsone—leprosy	0.000603	0.00315	CcSEcCtD
Doxorubicin—Oesophagitis—Thalidomide—leprosy	0.000602	0.00314	CcSEcCtD
Doxorubicin—Rash maculo-papular—Thalidomide—leprosy	0.000599	0.00313	CcSEcCtD
Doxorubicin—Pulmonary oedema—Thalidomide—leprosy	0.000587	0.00306	CcSEcCtD
Doxorubicin—Hypertonia—Thalidomide—leprosy	0.000578	0.00302	CcSEcCtD
Doxorubicin—NOS2—IL12-mediated signaling events—CD8A—leprosy	0.000574	0.0114	CbGpPWpGaD
Doxorubicin—Mental disability—Thalidomide—leprosy	0.000572	0.00299	CcSEcCtD
Doxorubicin—Sepsis—Thalidomide—leprosy	0.000572	0.00299	CcSEcCtD
Doxorubicin—POR—testis—leprosy	0.000565	0.00613	CbGeAlD
Doxorubicin—Erythema—Dapsone—leprosy	0.000563	0.00294	CcSEcCtD
Doxorubicin—Lymphadenopathy—Thalidomide—leprosy	0.000561	0.00293	CcSEcCtD
Doxorubicin—CYP1B1—skin of body—leprosy	0.000559	0.00607	CbGeAlD
Doxorubicin—Thrombophlebitis—Thalidomide—leprosy	0.000553	0.00289	CcSEcCtD
Doxorubicin—Blood alkaline phosphatase increased—Thalidomide—leprosy	0.00055	0.00287	CcSEcCtD
Doxorubicin—Diabetes mellitus—Thalidomide—leprosy	0.00055	0.00287	CcSEcCtD
Doxorubicin—Photosensitivity—Thalidomide—leprosy	0.000545	0.00284	CcSEcCtD
Doxorubicin—ABCC10—tendon—leprosy	0.000541	0.00588	CbGeAlD
Doxorubicin—Vascular purpura—Thalidomide—leprosy	0.000535	0.00279	CcSEcCtD
Doxorubicin—Eczema—Thalidomide—leprosy	0.000532	0.00278	CcSEcCtD
Doxorubicin—Vision blurred—Dapsone—leprosy	0.00053	0.00277	CcSEcCtD
Doxorubicin—Eye pain—Thalidomide—leprosy	0.00053	0.00277	CcSEcCtD
Doxorubicin—Cardiac failure congestive—Thalidomide—leprosy	0.000527	0.00275	CcSEcCtD
Doxorubicin—TOP2A—testis—leprosy	0.000526	0.00572	CbGeAlD
Doxorubicin—Renal failure acute—Thalidomide—leprosy	0.000518	0.00271	CcSEcCtD
Doxorubicin—Increased appetite—Thalidomide—leprosy	0.000509	0.00266	CcSEcCtD
Doxorubicin—Dermatitis exfoliative—Thalidomide—leprosy	0.000507	0.00265	CcSEcCtD
Doxorubicin—Vertigo—Dapsone—leprosy	0.000506	0.00264	CcSEcCtD
Doxorubicin—NOS2—Type II interferon signaling (IFNG)—IFNG—leprosy	0.000502	0.00995	CbGpPWpGaD
Doxorubicin—NOS2—IL23-mediated signaling events—IFNG—leprosy	0.000502	0.00995	CbGpPWpGaD
Doxorubicin—NQO1—testis—leprosy	0.000502	0.00545	CbGeAlD
Doxorubicin—Dermatitis bullous—Thalidomide—leprosy	0.0005	0.00261	CcSEcCtD
Doxorubicin—Purpura—Thalidomide—leprosy	0.000496	0.00259	CcSEcCtD
Doxorubicin—NQO1—nervous system—leprosy	0.000493	0.00535	CbGeAlD
Doxorubicin—Cough—Dapsone—leprosy	0.000491	0.00256	CcSEcCtD
Doxorubicin—Hypoglycaemia—Thalidomide—leprosy	0.00049	0.00256	CcSEcCtD
Doxorubicin—Cardiac failure—Thalidomide—leprosy	0.00049	0.00256	CcSEcCtD
Doxorubicin—Lethargy—Thalidomide—leprosy	0.000488	0.00255	CcSEcCtD
Doxorubicin—Cerebrovascular accident—Thalidomide—leprosy	0.000488	0.00255	CcSEcCtD
Doxorubicin—NOS2—IL23-mediated signaling events—CD4—leprosy	0.000485	0.00961	CbGpPWpGaD
Doxorubicin—NOS1—Monoamine Transport—TNF—leprosy	0.000484	0.00959	CbGpPWpGaD
Doxorubicin—Hyponatraemia—Thalidomide—leprosy	0.00048	0.00251	CcSEcCtD
Doxorubicin—Gastrointestinal haemorrhage—Thalidomide—leprosy	0.000478	0.0025	CcSEcCtD
Doxorubicin—Osteoarthritis—Thalidomide—leprosy	0.000478	0.0025	CcSEcCtD
Doxorubicin—Pain in extremity—Thalidomide—leprosy	0.000478	0.0025	CcSEcCtD
Doxorubicin—Diplopia—Thalidomide—leprosy	0.000478	0.0025	CcSEcCtD
Doxorubicin—Migraine—Thalidomide—leprosy	0.000471	0.00246	CcSEcCtD
Doxorubicin—Affect lability—Thalidomide—leprosy	0.000471	0.00246	CcSEcCtD
Doxorubicin—NOS2—IL12-mediated signaling events—HLA-DRB1—leprosy	0.000467	0.00926	CbGpPWpGaD
Doxorubicin—Face oedema—Thalidomide—leprosy	0.000462	0.00241	CcSEcCtD
Doxorubicin—Cardiac arrest—Thalidomide—leprosy	0.000455	0.00238	CcSEcCtD
Doxorubicin—Mood swings—Thalidomide—leprosy	0.000453	0.00237	CcSEcCtD
Doxorubicin—ABCC3—testis—leprosy	0.00045	0.00489	CbGeAlD
Doxorubicin—Ataxia—Thalidomide—leprosy	0.00045	0.00235	CcSEcCtD
Doxorubicin—ABCC10—testis—leprosy	0.000448	0.00487	CbGeAlD
Doxorubicin—Tachycardia—Dapsone—leprosy	0.000448	0.00234	CcSEcCtD
Doxorubicin—Blood creatinine increased—Thalidomide—leprosy	0.000448	0.00234	CcSEcCtD
Doxorubicin—NOS2—IL23-mediated signaling events—IL2—leprosy	0.000446	0.00885	CbGpPWpGaD
Doxorubicin—Dehydration—Thalidomide—leprosy	0.000445	0.00232	CcSEcCtD
Doxorubicin—ABCB1—blood vessel—leprosy	0.000443	0.00482	CbGeAlD
Doxorubicin—ABCC3—nervous system—leprosy	0.000442	0.0048	CbGeAlD
Doxorubicin—Liver function test abnormal—Thalidomide—leprosy	0.000442	0.00231	CcSEcCtD
Doxorubicin—Dry skin—Thalidomide—leprosy	0.000438	0.00229	CcSEcCtD
Doxorubicin—Orthostatic hypotension—Thalidomide—leprosy	0.000437	0.00228	CcSEcCtD
Doxorubicin—Hypokalaemia—Thalidomide—leprosy	0.000435	0.00227	CcSEcCtD
Doxorubicin—ABCC2—tendon—leprosy	0.000435	0.00472	CbGeAlD
Doxorubicin—Breast disorder—Thalidomide—leprosy	0.000432	0.00226	CcSEcCtD
Doxorubicin—Aspartate aminotransferase increased—Thalidomide—leprosy	0.000431	0.00225	CcSEcCtD
Doxorubicin—Toxic epidermal necrolysis—Thalidomide—leprosy	0.000431	0.00225	CcSEcCtD
Doxorubicin—CYP1B1—tendon—leprosy	0.000426	0.00462	CbGeAlD
Doxorubicin—Alanine aminotransferase increased—Thalidomide—leprosy	0.000422	0.0022	CcSEcCtD
Doxorubicin—Muscular weakness—Thalidomide—leprosy	0.000422	0.0022	CcSEcCtD
Doxorubicin—NOS1—Amyotrophic lateral sclerosis (ALS)—TNF—leprosy	0.000422	0.00836	CbGpPWpGaD
Doxorubicin—Abdominal distension—Thalidomide—leprosy	0.000416	0.00217	CcSEcCtD
Doxorubicin—Insomnia—Dapsone—leprosy	0.000415	0.00217	CcSEcCtD
Doxorubicin—Influenza—Thalidomide—leprosy	0.000413	0.00216	CcSEcCtD
Doxorubicin—Dysphagia—Thalidomide—leprosy	0.000413	0.00216	CcSEcCtD
Doxorubicin—Eosinophilia—Thalidomide—leprosy	0.000409	0.00214	CcSEcCtD
Doxorubicin—Pancreatitis—Thalidomide—leprosy	0.000405	0.00212	CcSEcCtD
Doxorubicin—Angina pectoris—Thalidomide—leprosy	0.000403	0.0021	CcSEcCtD
Doxorubicin—NQO1—Aryl Hydrocarbon Receptor Pathway—IFNG—leprosy	0.000402	0.00797	CbGpPWpGaD
Doxorubicin—Bronchitis—Thalidomide—leprosy	0.000398	0.00208	CcSEcCtD
Doxorubicin—Pancytopenia—Thalidomide—leprosy	0.000393	0.00205	CcSEcCtD
Doxorubicin—Neutropenia—Thalidomide—leprosy	0.000387	0.00202	CcSEcCtD
Doxorubicin—Upper respiratory tract infection—Thalidomide—leprosy	0.000384	0.00201	CcSEcCtD
Doxorubicin—SLC22A16—Transmembrane transport of small molecules—SLC11A1—leprosy	0.000384	0.00762	CbGpPWpGaD
Doxorubicin—CYP2B6—skin of body—leprosy	0.000384	0.00417	CbGeAlD
Doxorubicin—ABCC1—tendon—leprosy	0.000383	0.00416	CbGeAlD
Doxorubicin—Pollakiuria—Thalidomide—leprosy	0.000382	0.00199	CcSEcCtD
Doxorubicin—Photosensitivity reaction—Thalidomide—leprosy	0.000377	0.00197	CcSEcCtD
Doxorubicin—Weight increased—Thalidomide—leprosy	0.000376	0.00196	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Dapsone—leprosy	0.000376	0.00196	CcSEcCtD
Doxorubicin—Weight decreased—Thalidomide—leprosy	0.000374	0.00195	CcSEcCtD
Doxorubicin—Hyperglycaemia—Thalidomide—leprosy	0.000373	0.00195	CcSEcCtD
Doxorubicin—Pneumonia—Thalidomide—leprosy	0.000371	0.00194	CcSEcCtD
Doxorubicin—Infestation NOS—Thalidomide—leprosy	0.000369	0.00193	CcSEcCtD
Doxorubicin—Infestation—Thalidomide—leprosy	0.000369	0.00193	CcSEcCtD
Doxorubicin—Drowsiness—Thalidomide—leprosy	0.000369	0.00193	CcSEcCtD
Doxorubicin—Stevens-Johnson syndrome—Thalidomide—leprosy	0.000365	0.00191	CcSEcCtD
Doxorubicin—Body temperature increased—Dapsone—leprosy	0.000363	0.0019	CcSEcCtD
Doxorubicin—Abdominal pain—Dapsone—leprosy	0.000363	0.0019	CcSEcCtD
Doxorubicin—Renal failure—Thalidomide—leprosy	0.000362	0.00189	CcSEcCtD
Doxorubicin—Neuropathy peripheral—Thalidomide—leprosy	0.000361	0.00189	CcSEcCtD
Doxorubicin—ABCC2—testis—leprosy	0.00036	0.00391	CbGeAlD
Doxorubicin—Stomatitis—Thalidomide—leprosy	0.000359	0.00188	CcSEcCtD
Doxorubicin—Conjunctivitis—Thalidomide—leprosy	0.000358	0.00187	CcSEcCtD
Doxorubicin—NQO1—Aryl Hydrocarbon Receptor Pathway—IL2—leprosy	0.000357	0.00708	CbGpPWpGaD
Doxorubicin—Sweating—Thalidomide—leprosy	0.000353	0.00185	CcSEcCtD
Doxorubicin—CYP1B1—testis—leprosy	0.000352	0.00383	CbGeAlD
Doxorubicin—Haematuria—Thalidomide—leprosy	0.000351	0.00184	CcSEcCtD
Doxorubicin—Epistaxis—Thalidomide—leprosy	0.000348	0.00182	CcSEcCtD
Doxorubicin—CYP1B1—nervous system—leprosy	0.000346	0.00376	CbGeAlD
Doxorubicin—Sinusitis—Thalidomide—leprosy	0.000346	0.00181	CcSEcCtD
Doxorubicin—NOS2—ATF-2 transcription factor network—IFNG—leprosy	0.000346	0.00685	CbGpPWpGaD
Doxorubicin—Agranulocytosis—Thalidomide—leprosy	0.000344	0.0018	CcSEcCtD
Doxorubicin—NOS2—IL12-mediated signaling events—IFNG—leprosy	0.000341	0.00676	CbGpPWpGaD
Doxorubicin—Bradycardia—Thalidomide—leprosy	0.000337	0.00176	CcSEcCtD
Doxorubicin—Rhinitis—Thalidomide—leprosy	0.000332	0.00173	CcSEcCtD
Doxorubicin—Hepatitis—Thalidomide—leprosy	0.000331	0.00173	CcSEcCtD
Doxorubicin—NOS2—IL12-mediated signaling events—CD4—leprosy	0.000329	0.00653	CbGpPWpGaD
Doxorubicin—Hypoaesthesia—Thalidomide—leprosy	0.000329	0.00172	CcSEcCtD
Doxorubicin—Pharyngitis—Thalidomide—leprosy	0.000328	0.00172	CcSEcCtD
Doxorubicin—Urinary tract disorder—Thalidomide—leprosy	0.000327	0.00171	CcSEcCtD
Doxorubicin—Oedema peripheral—Thalidomide—leprosy	0.000326	0.0017	CcSEcCtD
Doxorubicin—NOS2—IL23-mediated signaling events—TNF—leprosy	0.000325	0.00644	CbGpPWpGaD
Doxorubicin—Urethral disorder—Thalidomide—leprosy	0.000324	0.00169	CcSEcCtD
Doxorubicin—Visual impairment—Thalidomide—leprosy	0.000319	0.00167	CcSEcCtD
Doxorubicin—ABCC1—testis—leprosy	0.000317	0.00344	CbGeAlD
Doxorubicin—Erythema multiforme—Thalidomide—leprosy	0.000313	0.00163	CcSEcCtD
Doxorubicin—Eye disorder—Thalidomide—leprosy	0.000309	0.00161	CcSEcCtD
Doxorubicin—Tinnitus—Thalidomide—leprosy	0.000309	0.00161	CcSEcCtD
Doxorubicin—Cardiac disorder—Thalidomide—leprosy	0.000307	0.0016	CcSEcCtD
Doxorubicin—NOS2—IL12-mediated signaling events—IL2—leprosy	0.000303	0.00601	CbGpPWpGaD
Doxorubicin—Angiopathy—Thalidomide—leprosy	0.0003	0.00157	CcSEcCtD
Doxorubicin—Immune system disorder—Thalidomide—leprosy	0.000299	0.00156	CcSEcCtD
Doxorubicin—Mediastinal disorder—Thalidomide—leprosy	0.000298	0.00156	CcSEcCtD
Doxorubicin—Chills—Thalidomide—leprosy	0.000297	0.00155	CcSEcCtD
Doxorubicin—Arrhythmia—Thalidomide—leprosy	0.000296	0.00154	CcSEcCtD
Doxorubicin—Alopecia—Thalidomide—leprosy	0.000292	0.00153	CcSEcCtD
Doxorubicin—Vomiting—Dapsone—leprosy	0.000292	0.00152	CcSEcCtD
Doxorubicin—ABCC6—Transmembrane transport of small molecules—SLC11A1—leprosy	0.000291	0.00577	CbGpPWpGaD
Doxorubicin—Mental disorder—Thalidomide—leprosy	0.00029	0.00151	CcSEcCtD
Doxorubicin—Malnutrition—Thalidomide—leprosy	0.000288	0.0015	CcSEcCtD
Doxorubicin—Headache—Dapsone—leprosy	0.000288	0.0015	CcSEcCtD
Doxorubicin—Flatulence—Thalidomide—leprosy	0.000284	0.00148	CcSEcCtD
Doxorubicin—Tension—Thalidomide—leprosy	0.000283	0.00148	CcSEcCtD
Doxorubicin—Dysgeusia—Thalidomide—leprosy	0.000282	0.00147	CcSEcCtD
Doxorubicin—Nervousness—Thalidomide—leprosy	0.00028	0.00146	CcSEcCtD
Doxorubicin—Back pain—Thalidomide—leprosy	0.000279	0.00146	CcSEcCtD
Doxorubicin—Muscle spasms—Thalidomide—leprosy	0.000277	0.00145	CcSEcCtD
Doxorubicin—Nausea—Dapsone—leprosy	0.000273	0.00142	CcSEcCtD
Doxorubicin—NOS3—SHP2 signaling—IFNG—leprosy	0.000272	0.00539	CbGpPWpGaD
Doxorubicin—Vision blurred—Thalidomide—leprosy	0.000271	0.00142	CcSEcCtD
Doxorubicin—Ill-defined disorder—Thalidomide—leprosy	0.000267	0.0014	CcSEcCtD
Doxorubicin—Anaemia—Thalidomide—leprosy	0.000266	0.00139	CcSEcCtD
Doxorubicin—Agitation—Thalidomide—leprosy	0.000265	0.00138	CcSEcCtD
Doxorubicin—YWHAG—SIDS Susceptibility Pathways—IL10—leprosy	0.000264	0.00523	CbGpPWpGaD
Doxorubicin—NOS1—Spinal Cord Injury—IFNG—leprosy	0.000263	0.00522	CbGpPWpGaD
Doxorubicin—ABCG2—testis—leprosy	0.000262	0.00285	CbGeAlD
Doxorubicin—NQO1—Aryl Hydrocarbon Receptor—TNF—leprosy	0.00026	0.00516	CbGpPWpGaD
Doxorubicin—NQO1—Aryl Hydrocarbon Receptor Pathway—TNF—leprosy	0.00026	0.00516	CbGpPWpGaD
Doxorubicin—Malaise—Thalidomide—leprosy	0.00026	0.00136	CcSEcCtD
Doxorubicin—Vertigo—Thalidomide—leprosy	0.000259	0.00135	CcSEcCtD
Doxorubicin—Syncope—Thalidomide—leprosy	0.000258	0.00135	CcSEcCtD
Doxorubicin—Leukopenia—Thalidomide—leprosy	0.000258	0.00135	CcSEcCtD
Doxorubicin—Palpitations—Thalidomide—leprosy	0.000255	0.00133	CcSEcCtD
Doxorubicin—ABCC10—Transmembrane transport of small molecules—SLC11A1—leprosy	0.000255	0.00505	CbGpPWpGaD
Doxorubicin—Loss of consciousness—Thalidomide—leprosy	0.000253	0.00132	CcSEcCtD
Doxorubicin—Cough—Thalidomide—leprosy	0.000251	0.00131	CcSEcCtD
Doxorubicin—Convulsion—Thalidomide—leprosy	0.00025	0.0013	CcSEcCtD
Doxorubicin—Hypertension—Thalidomide—leprosy	0.000249	0.0013	CcSEcCtD
Doxorubicin—Arthralgia—Thalidomide—leprosy	0.000245	0.00128	CcSEcCtD
Doxorubicin—Myalgia—Thalidomide—leprosy	0.000245	0.00128	CcSEcCtD
Doxorubicin—Chest pain—Thalidomide—leprosy	0.000245	0.00128	CcSEcCtD
Doxorubicin—Anxiety—Thalidomide—leprosy	0.000244	0.00128	CcSEcCtD
Doxorubicin—Unspecified disorder of skin and subcutaneous tissue—Thalidomide—leprosy	0.000244	0.00127	CcSEcCtD
Doxorubicin—Discomfort—Thalidomide—leprosy	0.000242	0.00127	CcSEcCtD
Doxorubicin—CYP2B6—testis—leprosy	0.000242	0.00263	CbGeAlD
Doxorubicin—NOS3—SHP2 signaling—IL2—leprosy	0.000242	0.00479	CbGpPWpGaD
Doxorubicin—Dry mouth—Thalidomide—leprosy	0.00024	0.00125	CcSEcCtD
Doxorubicin—CYP2B6—nervous system—leprosy	0.000238	0.00258	CbGeAlD
Doxorubicin—Confusional state—Thalidomide—leprosy	0.000237	0.00124	CcSEcCtD
Doxorubicin—Oedema—Thalidomide—leprosy	0.000235	0.00123	CcSEcCtD
Doxorubicin—NOS1—Alzheimers Disease—TNF—leprosy	0.000235	0.00466	CbGpPWpGaD
Doxorubicin—NOS1—Spinal Cord Injury—IL2—leprosy	0.000234	0.00464	CbGpPWpGaD
Doxorubicin—Infection—Thalidomide—leprosy	0.000234	0.00122	CcSEcCtD
Doxorubicin—NQO1—Apoptosis-related network due to altered Notch3 in ovarian cancer—TNF—leprosy	0.000232	0.0046	CbGpPWpGaD
Doxorubicin—Shock—Thalidomide—leprosy	0.000231	0.00121	CcSEcCtD
Doxorubicin—Nervous system disorder—Thalidomide—leprosy	0.000231	0.0012	CcSEcCtD
Doxorubicin—Thrombocytopenia—Thalidomide—leprosy	0.00023	0.0012	CcSEcCtD
Doxorubicin—Tachycardia—Thalidomide—leprosy	0.000229	0.0012	CcSEcCtD
Doxorubicin—Skin disorder—Thalidomide—leprosy	0.000228	0.00119	CcSEcCtD
Doxorubicin—Hyperhidrosis—Thalidomide—leprosy	0.000227	0.00119	CcSEcCtD
Doxorubicin—Anorexia—Thalidomide—leprosy	0.000224	0.00117	CcSEcCtD
Doxorubicin—NDUFS7—Metabolism—SDHD—leprosy	0.000223	0.00441	CbGpPWpGaD
Doxorubicin—NDUFS3—Metabolism—SDHD—leprosy	0.000223	0.00441	CbGpPWpGaD
Doxorubicin—Hypotension—Thalidomide—leprosy	0.00022	0.00115	CcSEcCtD
Doxorubicin—XDH—Selenium Micronutrient Network—IFNG—leprosy	0.000214	0.00425	CbGpPWpGaD
Doxorubicin—Musculoskeletal discomfort—Thalidomide—leprosy	0.000214	0.00112	CcSEcCtD
Doxorubicin—Insomnia—Thalidomide—leprosy	0.000213	0.00111	CcSEcCtD
Doxorubicin—Paraesthesia—Thalidomide—leprosy	0.000211	0.0011	CcSEcCtD
Doxorubicin—Dyspnoea—Thalidomide—leprosy	0.00021	0.00109	CcSEcCtD
Doxorubicin—NDUFS2—Metabolism—SDHD—leprosy	0.000209	0.00415	CbGpPWpGaD
Doxorubicin—Somnolence—Thalidomide—leprosy	0.000209	0.00109	CcSEcCtD
Doxorubicin—Dyspepsia—Thalidomide—leprosy	0.000207	0.00108	CcSEcCtD
Doxorubicin—Decreased appetite—Thalidomide—leprosy	0.000204	0.00107	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Thalidomide—leprosy	0.000203	0.00106	CcSEcCtD
Doxorubicin—Fatigue—Thalidomide—leprosy	0.000203	0.00106	CcSEcCtD
Doxorubicin—Constipation—Thalidomide—leprosy	0.000201	0.00105	CcSEcCtD
Doxorubicin—Pain—Thalidomide—leprosy	0.000201	0.00105	CcSEcCtD
Doxorubicin—NOS2—Spinal Cord Injury—IFNG—leprosy	0.000199	0.00394	CbGpPWpGaD
Doxorubicin—NOS3—Angiopoietin receptor Tie2-mediated signaling—TNF—leprosy	0.000198	0.00393	CbGpPWpGaD
Doxorubicin—Feeling abnormal—Thalidomide—leprosy	0.000194	0.00101	CcSEcCtD
Doxorubicin—CYP1B1—Aryl Hydrocarbon Receptor Pathway—IFNG—leprosy	0.000193	0.00383	CbGpPWpGaD
Doxorubicin—Gastrointestinal pain—Thalidomide—leprosy	0.000192	0.001	CcSEcCtD
Doxorubicin—Urticaria—Thalidomide—leprosy	0.000187	0.000975	CcSEcCtD
Doxorubicin—Body temperature increased—Thalidomide—leprosy	0.000186	0.000971	CcSEcCtD
Doxorubicin—Abdominal pain—Thalidomide—leprosy	0.000186	0.000971	CcSEcCtD
Doxorubicin—CYP2D6—testis—leprosy	0.00018	0.00195	CbGeAlD
Doxorubicin—CYP3A4—nervous system—leprosy	0.000179	0.00195	CbGeAlD
Doxorubicin—DHCR7—Metabolism—SDHD—leprosy	0.000178	0.00353	CbGpPWpGaD
Doxorubicin—CYP2D6—nervous system—leprosy	0.000177	0.00192	CbGeAlD
Doxorubicin—NOS2—Spinal Cord Injury—IL2—leprosy	0.000176	0.0035	CbGpPWpGaD
Doxorubicin—Hypersensitivity—Thalidomide—leprosy	0.000173	0.000905	CcSEcCtD
Doxorubicin—CYP1B1—Aryl Hydrocarbon Receptor Pathway—IL2—leprosy	0.000172	0.0034	CbGpPWpGaD
Doxorubicin—NOS1—Spinal Cord Injury—TNF—leprosy	0.00017	0.00338	CbGpPWpGaD
Doxorubicin—Asthenia—Thalidomide—leprosy	0.000169	0.000881	CcSEcCtD
Doxorubicin—NOS3—Corticotropin-releasing hormone—IL2—leprosy	0.000167	0.00331	CbGpPWpGaD
Doxorubicin—Pruritus—Thalidomide—leprosy	0.000166	0.000869	CcSEcCtD
Doxorubicin—CBR1—Metabolism—SDHD—leprosy	0.000166	0.00329	CbGpPWpGaD
Doxorubicin—Diarrhoea—Thalidomide—leprosy	0.000161	0.00084	CcSEcCtD
Doxorubicin—Dizziness—Thalidomide—leprosy	0.000155	0.000812	CcSEcCtD
Doxorubicin—Vomiting—Thalidomide—leprosy	0.000149	0.000781	CcSEcCtD
Doxorubicin—Rash—Thalidomide—leprosy	0.000148	0.000774	CcSEcCtD
Doxorubicin—Dermatitis—Thalidomide—leprosy	0.000148	0.000773	CcSEcCtD
Doxorubicin—Headache—Thalidomide—leprosy	0.000147	0.000769	CcSEcCtD
Doxorubicin—Nausea—Thalidomide—leprosy	0.00014	0.000729	CcSEcCtD
Doxorubicin—XDH—Selenium Micronutrient Network—TNF—leprosy	0.000139	0.00275	CbGpPWpGaD
Doxorubicin—ABCB1—testis—leprosy	0.000129	0.00141	CbGeAlD
Doxorubicin—NOS2—Spinal Cord Injury—TNF—leprosy	0.000129	0.00255	CbGpPWpGaD
Doxorubicin—ABCB1—nervous system—leprosy	0.000127	0.00138	CbGeAlD
Doxorubicin—CYP1B1—Aryl Hydrocarbon Receptor—TNF—leprosy	0.000125	0.00248	CbGpPWpGaD
Doxorubicin—CYP1B1—Aryl Hydrocarbon Receptor Pathway—TNF—leprosy	0.000125	0.00248	CbGpPWpGaD
Doxorubicin—NOS1—Disease—SLC11A1—leprosy	0.000121	0.0024	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—CD40LG—leprosy	0.000105	0.00208	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—IL10—leprosy	0.000105	0.00208	CbGpPWpGaD
Doxorubicin—YWHAG—Apoptosis—TNF—leprosy	0.000101	0.002	CbGpPWpGaD
Doxorubicin—YWHAG—SIDS Susceptibility Pathways—TNF—leprosy	0.0001	0.00199	CbGpPWpGaD
Doxorubicin—ABCC3—Transmembrane transport of small molecules—SLC11A1—leprosy	9.86e-05	0.00195	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—SDHD—leprosy	9.69e-05	0.00192	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—SDHD—leprosy	9.35e-05	0.00185	CbGpPWpGaD
Doxorubicin—NOS2—Disease—SLC11A1—leprosy	9.13e-05	0.00181	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—SDHD—leprosy	8.69e-05	0.00172	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—HLA-DRB1—leprosy	8.44e-05	0.00167	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—SLC11A1—leprosy	8.39e-05	0.00166	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—SDHD—leprosy	7.9e-05	0.00157	CbGpPWpGaD
Doxorubicin—ABCC2—Transmembrane transport of small molecules—SLC11A1—leprosy	7.81e-05	0.00155	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—RIPK2—leprosy	7.73e-05	0.00153	CbGpPWpGaD
Doxorubicin—ABCC1—Transmembrane transport of small molecules—SLC11A1—leprosy	7.72e-05	0.00153	CbGpPWpGaD
Doxorubicin—NOS1—Hemostasis—IL2—leprosy	7.3e-05	0.00145	CbGpPWpGaD
Doxorubicin—NOS3—Disease—SLC11A1—leprosy	7.09e-05	0.00141	CbGpPWpGaD
Doxorubicin—ABCG2—Transmembrane transport of small molecules—SLC11A1—leprosy	6.8e-05	0.00135	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—SDHD—leprosy	6.41e-05	0.00127	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—IFNG—leprosy	6.16e-05	0.00122	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—SDHD—leprosy	6.14e-05	0.00122	CbGpPWpGaD
Doxorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TNF—leprosy	5.98e-05	0.00118	CbGpPWpGaD
Doxorubicin—NOS2—Hemostasis—IL2—leprosy	5.5e-05	0.00109	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—IL2—leprosy	5.47e-05	0.00109	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—SDHD—leprosy	4.81e-05	0.000954	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—SDHD—leprosy	4.65e-05	0.000923	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—SLC11A1—leprosy	4.32e-05	0.000856	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—RIPK2—leprosy	4.28e-05	0.000849	CbGpPWpGaD
Doxorubicin—NOS3—Hemostasis—IL2—leprosy	4.27e-05	0.000847	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—SDHD—leprosy	4.23e-05	0.00084	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—TNF—leprosy	3.99e-05	0.000791	CbGpPWpGaD
Doxorubicin—NOS1—Disease—CD4—leprosy	3.84e-05	0.000761	CbGpPWpGaD
Doxorubicin—ABCB1—Transmembrane transport of small molecules—SLC11A1—leprosy	3.67e-05	0.000728	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—RIPK2—leprosy	3.62e-05	0.000717	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—SDHD—leprosy	3.1e-05	0.000615	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—IL2—leprosy	3.09e-05	0.000614	CbGpPWpGaD
Doxorubicin—NOS2—Disease—CD4—leprosy	2.9e-05	0.000574	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—CD4—leprosy	2.66e-05	0.000528	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—SDHD—leprosy	2.29e-05	0.000454	CbGpPWpGaD
Doxorubicin—NOS3—Disease—CD4—leprosy	2.25e-05	0.000446	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—SDHD—leprosy	2.16e-05	0.000428	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—leprosy	1.97e-05	0.00039	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—IL2—leprosy	1.72e-05	0.00034	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—IL2—leprosy	1.45e-05	0.000287	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—SDHD—leprosy	1.41e-05	0.00028	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—CD4—leprosy	1.37e-05	0.000272	CbGpPWpGaD
